Interestingly, an early study demonstrated a synergy between PHF8 and HER2 signaling in the development HER2-positive breast cancer, revealing significant therapeutic implications for targeting PHF8 in HER2-positive breast cancer to overcome therapy resistance [52]. Here, ERBB2 is linked to breast carcinoma.